Psychedelics

485 posts
Psychedelic pills

Canadian psychedelic stock to supply MDMA to Yale

Canadian psychedelic stock PharmAla Biotech (CSE:MDMA) is up after signing a contract to supply MDMA for a clinical trial at Yale University.
MindBio Therapeutics chief executive officer Justin Hanka.

MindBio advances world-first psychedelic microdosing clinical trials

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Psilocybin mushrooms

Optimi will test its psilocybin on frontline healthcare workers

Health Canada clears psychedelics stock Optimi Health (CSE:OPTI) to test its psilocybin on frontline healthcare workers.
A hand holding blocks that spells out PTSD

Optimi Health ships first MDMA capsules to Australia to treat PTSD

Optimi Health (CSE:OPTI) reveals it has completed the inaugural export of its GMP-validated MDMA capsules to Australia.

MindBio’s microdosed LSD reduces depression post treatment

MindBio (CSE:MBIO), a psychedelic healthcare stock, reports a sustained 65% reduction in depressive symptoms in its phase 2A clinical trial.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.
Red Light Holland

Red Light Holland completes psilocybin extraction report

Red Light Holland (CSE:TRIP) reveals it has successfully completed the comprehensive extraction protocol with PharmAla Biotech (CSE:MDMA).

FDA committee rejects MDMA drug, discounting psychedelic stocks

A committee of the U.S. FDA rejects a drug application to treat PTSD using MDMA-assisted therapy, causing numerous stocks to fall.

Record monthly revenue positions edibles company for success

Canadian cannabis edibles are generating traction and Indiva (TSXV:NDVA) remains poised to capitalize on this ever-growing industry.

Optimi Health cleared to supply MDMA and psilocybin worldwide

Optimi Health (CSE:OPTI) earns a Health Canada Drug Establishment Licence to produce and sell its MDMA and psilocybin capsules in Australia.

Numinus approved for pioneering MDMA-based clinical trial

Numinus Wellness (TSX:NUMI) receives Health Canada approval for a clinical trial examining group models in MDMA-assisted psychotherapy.

Red Light Holland and PharmAla notch psilocybin extraction

Red Light Holland (CSE:TRIP) reveals it has successfully completed the first phase of psilocybin extraction to PharmAla Biotech (CSE:MDMA).
Optimi Health mushrooms

Optimi Health to advance psychedelic clinical trials

Optimi Health (CSE:OPTI) signs letter of intent with ATMA Journey Centers to advance its psilocybin extract into a psilocybin clinical trial.

Optimi Health certified for increased MDMA capsule dosages

Optimi Health (CSE:OPTI) confirms its formulated MDMA meets Good Manufacturing Practice specifications after third-party laboratory testing.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Red Light Holland and Costco Canada partner on mushroom kits

Red Light Holland (CSE:TRIP) partners with Costco Canada to launch Mega Block, a 2-kilogram home-grow mushroom kit, in late May.

CCrest Labs receives Red Light Holland’s largest psilocybin order

Red Light Holland's (CSE:TRIP) largest shipment to date of 5 kilograms of psilocybin truffles has been received by CCrest Labs in Montreal.

Red Light Holland reports record psilocybin shipment

Psychedelics stock Red Light Holland (CSE:TRIP) exports 5 kilograms of natural psilocybin truffles to CCrest Laboratories in Montreal.

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.